You are here:Home-Inhibitors & Agonists-JAK/STAT Signaling-Pim

Request The Product List ofPim Pim

Cat. No. Product Name CAS No. Information
PC-35492

HS56

922050-57-5

HS56 (Pim-DAPK3 inhibitor HS56) is a potent, dual Pim/DAPK3 inhibitor with Ki of 72 nM (Pim-3) and 315 nM (DAPK3), shows micromolar potency toward Pim-1 and Pim-2 (Ki=1.5 and 17 uM); displays a high degree of selectivity for DAPKs and Pims against a panel of 468 kinases, with only two off-target interactions TYK2 and GAK; also displays no significant inhibition or activation of nicotinic, adrenergic, or muscarinic receptors at 10 uM; HS56 delayed force onset, decreased contractile force, and reduced LC20 phosphorylation in excised rat caudal arterial VSM tissues, lowers blood pressure in spontaneously hypertensive mice without affecting heart rate.

PC-70113

LGB-321

1210416-93-5

LGB-321 (LGB321) is a potent and specific pan-Pim inhibitor with Ki of 1/2.1/0.8 pM for Pim1/2/3, respectively; inhibits proliferation, mTOR-C1 signaling and phosphorylation of BAD in PIM2-dependent MM cell lines; shows activity in cell lines derived from diverse hematological lineages, including ALL, AML, NHL; shows activity in the KG-1 AML xenograft model, and synergizes with cytarabine.

PC-45110

GDC-0339

1428569-85-0

GDC-0339 is a novel small molecule pan-Pim kinase inhibitor that was discovered as a potential treatment for multiple myeloma.

Blood Cancer

Preclinical

PC-45605

PIM-447

1210608-43-7

A highly potent and selective inhibitor of pan-Pim with IC50s of 6/18/9 pM for Pim/1/2/3 respectively; induces apoptosis by a decrease in phospho-Bad Ser112 and c-Myc levels and the inhibition of mTORC1 pathway; significantly reduces the tumor burden and prevents tumor-associated bone loss in a murine model of human myeloma.

Blood Cancer

Phase 2 Clinical

PC-36029

VS-II-173

1627962-21-3 VS-II-173 is a highly potent Pim1 and Pim3 inhibitor with IC50 of 70 and 20 nM respectively, and a potent and selective inducer of AML cell death (IC50=5.5 uM, Molm-13 cell); acts synergistically with the anthracycline daunorubicin, and additively with a number of other anti-cancer drugs; attenuates phosphorylation of Pim kinase substrates, shows towards cell lines harboring the FLT3-ITD mutation (Molm-13, FLT3-ITD heterozygous and MV4-11 FLT3-ITD homozygous) with EC50 of 2-3 uM; also induces cell death also in AML patient blasts, including blast carrying high-risk FLT3-ITD mutation.
PC-35980

Pim inhibitor 28

Pim inhibitor 28 is a potent, selective inhibitor of Pim1/2 with IC50 of 0.05 nM for both, demonstrates on-target Pim activity in an in vivo pharmacodynamic assay with significant inhibition of BAD phosphorylation in KMS-12-BM multiple myeloma tumors.
PC-35943

pan-PIM inhibitor 17

1681021-52-2 pan-PIM inhibitor 17 is a potent, selective, orally available inhibitor of Pim kinase with IC50 of 0.8, 5.1 and 1.8 nM for Pim1, 2 and 3, respectively; disaplays broad selectivity in an internal panel of 192 kinases, only eight kinases were inhibited above 50% at 1 uM; demonstrates cellular biomarker pS6 inhibition with EC50 of 27 nM, shows tumor growth inhibition in a KG1 tumor-bearing mouse model.

Request The Product List

* Indicates a Required FieldYour information is safe with us.

  • *Product List:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Country:
  • Additional Information:
Contact Us sales@probechem.com